📊 MBOT Key Takeaways
Is MBOT a Good Investment? Thesis Analysis
Microbot Medical is a pre-revenue stage medical device company with minimal commercialization ($2K revenue), burning $13M annually with only 3.9M in cash reserves providing less than 4 months of runway. Despite strong balance sheet composition and zero debt burden, the company faces existential risk from unsustainable cash burn and inability to generate meaningful revenue, indicating significant development or commercialization challenges.
Why Buy MBOT? Key Strengths
- Negligible debt with 0.03x debt-to-equity ratio and strong balance sheet structure
- Adequate current ratio of 23.33x indicating no immediate liquidity crisis
- Large asset base of 81.5M suggesting accumulated R&D investments in surgical robotics technology
MBOT Investment Risks to Consider
- Severe cash burn of $13M annually with only $3.9M cash reserves - approximately 3.6 months runway
- Essentially pre-revenue stage with only $2K in reported revenue indicating failed commercialization of surgical robotics platform
- Negative operating cash flow of $13M and deteriorating net loss position despite marginal revenue growth
- Extended period of unprofitability with -16.9% ROE suggests capital is being destroyed, not deployed efficiently
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Revenue generation and path to commercialization of surgical robotics products
- Operating cash flow improvement and timeline to cash flow breakeven
MBOT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 23.33x current ratio provides a solid financial cushion.
MBOT Profitability Ratios
MBOT vs Healthcare Sector
How Microbot Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MBOT Overvalued or Undervalued?
Based on fundamental analysis, Microbot Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MBOT Balance Sheet & Liquidity
MBOT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Microbot Medical Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MBOT Growth Metrics (YoY)
MBOT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2016 | $32.8K | -$4.2M | N/A |
| Q2 2016 | $29.3K | $2.5M | N/A |
| Q1 2016 | $21.0K | -$9.4M | N/A |
| Q3 2015 | $37.0K | -$2.6M | N/A |
| Q1 2015 | $21.0K | -$7.6M | N/A |
| Q3 2014 | $171.4K | -$2.8M | N/A |
| Q2 2014 | $218.7K | -$5.9M | N/A |
| Q1 2014 | $208.6K | -$6.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MBOT Capital Allocation
MBOT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Microbot Medical Inc. (CIK: 0000883975)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBOT
What is the AI rating for MBOT?
Microbot Medical Inc. (MBOT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBOT's key strengths?
Claude: Negligible debt with 0.03x debt-to-equity ratio and strong balance sheet structure. Adequate current ratio of 23.33x indicating no immediate liquidity crisis.
What are the risks of investing in MBOT?
Claude: Severe cash burn of $13M annually with only $3.9M cash reserves - approximately 3.6 months runway. Essentially pre-revenue stage with only $2K in reported revenue indicating failed commercialization of surgical robotics platform.
What is MBOT's revenue and growth?
Microbot Medical Inc. reported revenue of $2.0K.
Does MBOT pay dividends?
Microbot Medical Inc. does not currently pay dividends.
Where can I find MBOT SEC filings?
Official SEC filings for Microbot Medical Inc. (CIK: 0000883975) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBOT's EPS?
Microbot Medical Inc. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBOT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Microbot Medical Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBOT stock overvalued or undervalued?
Valuation metrics for MBOT: ROE of -16.9% (sector avg: 15%), net margin of -657,100.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBOT stock in 2026?
Our dual AI analysis gives Microbot Medical Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBOT's free cash flow?
Microbot Medical Inc.'s operating cash flow is $-13.0M, with capital expenditures of $60.0K. FCF margin is -655,300.0%.
How does MBOT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -657,100.0% (avg: 12%), ROE -16.9% (avg: 15%), current ratio 23.33 (avg: 2).